Kansas Clinical Trials

A listing of Kansas clinical trials actively recruiting patient volunteers.

Sharing its biggest city of Kansas City with its neighbors in Missouri, Kansas is the iconic prairie state and childhood home of Superman. Topeka, Wichita, and Overland Park are some of the other cities, with Overland Park serving as a hub for technology businesses. Kansas has long been one of the most important agricultural centers of the nation, producing more wheat than any other state. These days, it also contributes to aerospace research through an astonishing number of local companies. Healthcare has been growing rapidly in Kansas, with University of Kansas Hospital leading the way as the state's largest provider.

Search by Name
Search
Filter by Condition
1022 trials found

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

Conditions: Parkinsons Disease

Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects

NCT04783753

Non-randomized, 3-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of itraconazole, carbamazepine, or quinidine on the PK and safety of EDP-514 in healthy adult subjects.

Conditions: Hepatitis B

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

NCT04786444

This is a prospective, randomized, double-blinded, multicenter Phase 3 clinical study investigating three Lots of VLA1553 at the final dose. Overall, approximately 393 healthy subjects aged 18 to 45 years will be enrolled into the study, approximately 131 subjects per VLA1553 Lot.

Conditions: Chikungunya Virus Infection

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

NCT04788511

This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in people taking semaglutide (a new medicine) to people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need t ...

Conditions: Obesity

LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

NCT04790344

The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.

Conditions: Heart Failure
Phase: Not Applicable

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

NCT04795531

This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin degludec taken daily. Participants will get their study medicine in an injection pen. Participants will get a pen for weekly injection and one for daily injection. One will be icodec or degludec and the ot ...

Conditions: Diabetes Mellitus, Type 2

A Study to Evaluate Safety and Effectiveness of mRNA-1273 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

NCT04796896

The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children in 2 doses, 28 days apart.

Conditions: SARS-CoV-2
Phase: Phase 2/3

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

NCT04798001

This study evaluates an investigational vaccine that is designed to protect humans against infection with SARS-CoV-2, the novel coronavirus causing COVID-19 disease. The investigational vaccine, MV-014-212, is a live attenuated vaccine against respiratory syncytial virus (RSV) that is expressing the spike (S) protein of SARS-CoV-2. MV-014-212 is administered as drops or a spray in the nose. Specifically, this study analyzes the safety of, and the immune response to, the vaccine when administered ...

Conditions: Covid19

Chronic Pain, Opioid Use, and Epidermal Nerve Fiber Density

NCT04801498

This pilot study is being performed to examine whether epidermal axons are altered in patients taking opioid therapy for chronic non-cancer pain, and if epidermal axonal changes predict heightened pain sensitivity.

Conditions: Chronic Pain, Opioid Use, Nerve Disorders

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

NCT04804033

The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.

Conditions: Migraine
Phase: Phase 2/3

Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers

NCT04808622

Randomized, double-blind, placebo-controlled, pharmacokinetic, pharmacodynamic study. Subjects will be randomized to TSC or placebo to determine the effect of Trans Sodium Crocetinate (TSC) on Transcutaneous Oximetry Measurements (tcpO2) following a single administration of TSC in subjects breathing oxygen (O2).

Conditions: Transcutaneous Oxygen Monitoring

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age

NCT04816643

This is a Phase 1/2/3 study in healthy children <12 years of age. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants <6 months of age may subsequently be evaluated.

Conditions: SARS-CoV-2 Infection, COVID-19